Dr Reddy's Labs gets USFDA inspection closure report for Srikakulam plant
New Delhi: Drug major Dr. Reddy''s Laboratories on Friday said the US health regulator has closed inspection of its manufacturing facility in Srikakulam, Andhra Pradesh.
The US Food and Drug Administration (USFDA) had issued a warning letter to the facility in November 2015, after inspecting it in 2014.
"We have received the establishment inspection report from the USFDA, for the Srikakulam facility, indicating closure of the audit and the inspection classification of this facility," Dr. Reddy''s Laboratories said in a regulatory filing.
With this, all facilities under warning letters are now determined as 'voluntary action indicated', the drug major said.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.